MEF2B is amplified in 9% of ovarian carcinomas (28 out of 311 cases, TCGA provisional data11, 12), 5% of uterine carcinomas (11 out of 240 cases13), 5% of adrenocortical carcinomas (4 out of 88 cases, TCGA provisional data11, 12) and 3% of oesophageal carcinomas (6 out of 184 cases, TCGA provisional data11, 12), indicating that MEF2B may act as an oncogene in these carcinomas. Here, MEF2B is linked to ovarian carcinoma.